Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Indivior PLC (2IVB)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
17.5000 0.0000    0.00%
22/04 - Delayed Data. Currency in EUR ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 17.5000 / 17.7000
  • Day's Range: 17.5000 - 17.5000
Type:  Equity
Market:  Germany
ISIN:  GB00BN4HT335 
S/N:  A3DWFC
Indivior PLC 17.5000 0.0000 0.00%

Indivior PLC Company Profile

 
Read the Indivior PLC company profile to learn more about the business and the management team. View Indivior PLC facts about employee data, company products and services, and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

1000

Equity Type

ORD

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Contact Information

Address 10710 Midlothian Turnpike Suite 125
North Chesterfield, 23235
United States
Phone 804 379 1090
Fax -

Top Executives

Name Age Since Title
Graham C. Hetherington 65 2019 Independent Chairman
Peter James Jonathan Bains 67 2019 Independent Non-Executive Director
Mark Crossley - 2014 CEO & Executive Director
Joanna Susan Le Couilliard 61 2021 Independent Non-Executive Director
Ryan Preblick - 2020 CFO & Executive Director
Barbara A. Ryan 64 2022 Independent Non-Executive Director
Mark P. Stejbach 61 2021 Independent Non-Executive Director
Juliet Thompson 58 2021 Senior Independent Director
Jerome Jay Lande 48 2021 Non-Executive Director
Keith Humphreys - 2023 Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

INDV Price Commentary

Write your thoughts about Indivior PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Justin Langshaw
Justin Langshaw Oct 10, 2022 8:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
anyone know what's happened here?
Al Al
Al Al Jul 10, 2020 18:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What a poor business. Extrodinary debt. No cash.
Glauco Pazzaglini
Glauco Pazzaglini Jul 10, 2020 18:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
totally agree. this is the crazy stock.
Kevin Heng
Kevin Heng Apr 10, 2019 13:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
potential 3 bln fines in US. company is broke.
Tariq Khan
Tariq Khan Apr 10, 2019 13:33
Saved. See Saved Items.
This comment has already been saved in your Saved Items
company tried settlement but rejected.the previous parent company has already set aside 400 million.
Tariq Khan
Tariq Khan Apr 10, 2019 9:42
Saved. See Saved Items.
This comment has already been saved in your Saved Items
any ideas
Tariq Khan
Tariq Khan Apr 10, 2019 9:42
Saved. See Saved Items.
This comment has already been saved in your Saved Items
where this will stop
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email